Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $166.5 million.

  • Amylyx Pharmaceuticals' Net Cash Flow rose 632565.45% to $166.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.4 million, marking a year-over-year increase of 34190.35%. This contributed to the annual value of -$91.6 million for FY2024, which is 18523.93% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Net Cash Flow stood at $166.5 million, which was up 632565.45% from -$2.3 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Net Cash Flow high stood at $166.5 million for Q3 2025, and its period low was -$112.4 million during Q3 2023.
  • Moreover, its 5-year median value for Net Cash Flow was $461000.0 (2024), whereas its average is $11.2 million.
  • Within the past 5 years, the most significant YoY rise in Amylyx Pharmaceuticals' Net Cash Flow was 632565.45% (2025), while the steepest drop was 396572.67% (2025).
  • Amylyx Pharmaceuticals' Net Cash Flow (Quarter) stood at -$26.5 million in 2021, then plummeted by 72.54% to -$45.7 million in 2022, then surged by 175.92% to $34.7 million in 2023, then crashed by 82.48% to $6.1 million in 2024, then soared by 2637.16% to $166.5 million in 2025.
  • Its last three reported values are $166.5 million in Q3 2025, -$2.3 million for Q2 2025, and -$17.8 million during Q1 2025.